New combo therapy aims to shrink kidney tumors in Late-Stage trial
NCT ID NCT07469683
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the experimental drug SLC-3010 to the standard drug axitinib works better than axitinib alone for people with advanced clear cell kidney cancer that has worsened after first treatment. About 78 adults will be randomly assigned to one of the two groups. The main goal is to see if the combination shrinks tumors more effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Severance Hospital
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple screening program could transform cancer aftercare
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a simple text message transform cancer care?
- Can modern Radiotherapy's late effects be predicted?
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?